Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1391287 | 0.91 | MAPT (0.66) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1391333 | 0.82 | MAPT (0.58) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1391443 | 0.82 | MAPK1 (0.59) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL10243636 | 0.82 | MAPT (0.79) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1390765 | 0.82 | ALDH1A1 (0.54) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1391251 | 0.81 | ALDH1A1 (0.53) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1391434 | 0.80 | MAPT (0.68) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1391547 | 0.79 | MAPK1 (0.64) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1391154 | 0.78 | SMN1; SMN2 (0.77) | MAPK1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL1390712 | 0.78 | MAPT (0.65) | MAPK1MAPTNPSR1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | MAPK1 2676/4885MAPT 3654/4885NPSR1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.